> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# New BD COR Molecular Diagnostic Platform Cleared
- URL: https://www.fdaweb.com/new-bd-cor-molecular-diagnostic-platform-cleared/
- Published: 2022-05-13T12:00:00.000Z
- Updated: 2026-09-14T17:44:30.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5151814

FDA has cleared a BD (Becton, Dickinson) 510(k) for its new automated, high-throughput infectious disease molecular diagnostics platform. The first test available on the new BD COR system is the BD CTGCTV2 molecular assay, a single test that detects the three most prevalent non-viral sexually transmitted infections — *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis*.

The device eliminates the need to sort specimens, freeing up time for other lab processes, according to the company. It allows 1,700 specimens to be loaded, with onboard capacity for reagents and samples that provide more than seven hours of unimpeded system processing. The system can deliver up to 1,000 sample results in 24 hours, eliminating multiple manual interactions per shift that were traditionally required, Medtronic says.